Three independent discounted-cash-flow-style models value Alnylam Pharmaceuticals, Inc. every trading day. 0 of 3 currently price ALNY above its market price.
| Free Cash Flow model | $-708.46 |
| Excess Profit model | $-763.76 |
| Residual Earnings model | $-0.63 |
| Dividend Discount model | — |
| Piotroski F-Score | 6 / 9 |
| Return on invested capital | +19.2% |
| Net debt / EBITDA | -0.7× |
| Gross margin | +81.6% |
| Revenue CAGR | +53.0% |
| Cash conversion | 1.7× |
| Dividend yield | — |
| Buyback yield | -2.4% |
These are StockKitty's default assumptions. In the app, the models recompute live as you adjust growth, discount rates, and margins — and the AI explains the bull case, bear case, and quality picture.
Open ALNY in StockKitty